On January 8, 2015 Otsuka Pharmaceutical reported that the exclusive licensing contract that has been in effect with OncoTherapy Science, Inc. (OTS) for the development, manufacture, and marketing of a peptide therapeutic vaccine for the treatment of pancreatic cancer, will be allowed to expire, following 180-day prior notification, at the scheduled end date of the contract period (Press release Otsuka, JAN 8, 2015, View Source [SID:1234501293]). A sublicensing contract which has been in effect with Fuso Pharmaceutical Industries, Ltd. for the manufacture and marketing in Japan of OTS102, a therapeutic vaccine, will also be allowed to expire on the same date.

Otsuka will continue its efforts in oncology as a priority area. This will include the development of the peptide therapeutic vaccine OCV-C02, for which a phase 1 clinical study is currently underway in colon cancer based on a contract with OTS.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!